Here is a summary of the latest analyst ratings from Wall Street that are most closely watched and have significant market impact. The following are today's key rating changes compiled by The Fly that investors should focus on.
Top Five Rating Upgrades
Northland Securities upgraded Palantir Technologies Inc. (PLTR) from Market Perform to Outperform, raising its price target from $185 to $190. The upgrade was driven by the company's "exceptionally strong" fourth-quarter performance. Daiwa Securities upgraded Visa (V) from Neutral to Outperform, maintaining its price target of $370. Based on Visa's Q1 earnings report released on January 29, Daiwa revised its earnings forecasts, implementing a "slight upward adjustment" to its medium-term performance estimates. Concurrently, Daiwa upgraded MasterCard (MA) from Neutral to Outperform, increasing its price target from $605 to $610. Morgan Stanley upgraded Affirm Holdings, Inc. (AFRM) from Equal-Weight to Overweight, while lowering its price target from $83 to $76. The firm informed investors in its research note that the stock's recent weakness has created an "extremely attractive risk-reward profile." Citigroup upgraded JetBlue Airways (JBLU) from Sell to Neutral and raised its price target from $4 to $6. Citi believes the stock carries "upside risk" and that JetBlue is one of the few airlines that still retains the "potential for strategic optionality." DA Davidson upgraded Q2 Hldgs Inc (QTWO) from Neutral to Buy, maintaining its price target of $82. The firm clarified that its rating change was not a judgment on the company's upcoming Q4 earnings but rather reflected the view that the stock's pullback over the past 6-8 months has created a more attractive entry point.
Top Five Rating Downgrades
Piper Sandler downgraded Adobe (ADBE) from Overweight to Neutral, significantly slashing its price target from $470 to $330. This adjustment was part of a change in the analyst coverage team. The firm expressed concern that market narratives around seat compression and generative AI could pressure the stock's valuation multiples, while emphasizing that the downgrade was "not a reflection" of the company's Q4 performance. RBC Capital Markets downgraded Elevance Health (ELV) from Outperform to Sector Perform, lowering its price target from $392 to $358. Although the firm was "encouraged" by management's confidence in the core business, the weaker-than-expected 2026 guidance and subdued subsequent margin outlook prompted a move to the sidelines. Bank of America downgraded Figure Technology Solutions (FIGR) from Neutral to Underperform, slightly reducing its price target from $43 to $42. BofA noted that the stock has surged 109% in the five months since its IPO, while Coinbase (COIN) shares fell 41% over the same period, creating a valuation gap that is "too large," which was the primary reason for the downgrade. BNP Paribas downgraded Exxon Mobil (XOM) from Neutral to Underperform, while paradoxically raising its price target from $114 to $125. The bank cited valuation as the core reason for the downgrade, noting that Exxon Mobil's current P/E ratio is at a five-year high. Roth Capital downgraded Coterra Energy Inc. (CTRA) from Buy to Neutral, lowering its price target from $30 to $28. Although Devon Energy's (DVN) acquisition offer for Coterra was "slightly below market expectations," Roth Capital believes the company is unlikely to receive a higher bid from Devon or any other suitor at this stage.
Top Five Initiation of Coverage Ratings
Morgan Stanley initiated coverage on Walt Disney (DIS) with an Overweight rating and a $135 price target. The firm believes Disney offers an "extremely attractive" risk-reward profile at current price levels, as it anticipates double-digit growth in Disney's adjusted earnings for fiscal 2026 and beyond. Wedbush initiated coverage on TaskUs Inc. (TASK) with an Outperform rating and a $15 price target, identifying an attractive risk-reward investment opportunity. Wedbush initiated coverage on Staar Surgical (STAA) with a Neutral rating and a $26 price target. While the firm acknowledged the stock's attractive valuation—trading at a significant discount to both a previously failed takeover bid and the $50 per share intrinsic value estimate publicly disclosed by shareholder Broadwood Partners—Wedbush also highlighted associated risks with the company's business recovery in China. Guggenheim Securities initiated coverage on Sagimet Biosciences Inc. (SGMT) with a Buy rating and a $27 price target. The firm believes the company's fatty acid synthase inhibitor pipeline holds "two unique and underappreciated potential blockbuster opportunities" in treating late-stage NASH (F4 stage) and moderate-to-severe acne. Liflinq Securities initiated coverage on Aktis Oncology (AKTS) with an Outperform rating and a $31 price target. The firm expressed a positive outlook on Aktis Oncology's prospects, noting the company is focused on expanding the therapeutic target landscape for radiopharmaceuticals, with pipeline candidates potentially becoming first-in-class innovations. Additionally, Bank of America, J.P. Morgan, and TD Cowen also initiated coverage on the stock with ratings equivalent to "Buy."
Comments